Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.59 |
| ▸ | KIT | P10721 | 8/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.44 |
| ▸ | LCK | P06239 | 4/20 | 0.44 |
| ▸ | AXL | P30530 | 4/20 | 0.44 |
| ▸ | FLT3 | P36888 | 4/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.44 |
| ▸ | PLK4 | O00444 | 2/20 | 0.44 |
| ▸ | STK25 | O00506 | 2/20 | 0.44 |
| ▸ | RIOK3 | O14730 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | GAK | O14976 | 2/20 | 0.44 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.44 |
| ▸ | MUSK | O15146 | 2/20 | 0.44 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856282 | 0.92 | CSF1R (0.57) | CSF1RKITCYP2C19CYP3A4NTRK1 | |
| SCHEMBL1855569 | 0.91 | CSF1R (0.58) | CSF1RKITCYP2C19CYP3A4NTRK1 | |
| SCHEMBL1855396 | 0.90 | CSF1R (0.59) | CSF1RKITCYP2C19CYP3A4NTRK1 | |
| SCHEMBL1865625 | 0.90 | CSF1R (0.57) | CSF1RKITCYP2C19CYP3A4NTRK1 | |
| SCHEMBL1859661 | 0.89 | CSF1R (0.59) | CSF1RKITCYP2C19CYP3A4NTRK1 | |
| SCHEMBL18307002 | 0.89 | KIT (0.55) | CSF1RKITCYP2C19CYP3A4NTRK1 | |
| SCHEMBL2938195 | 0.88 | KIT (0.57) | CSF1RKITCYP2C19CYP3A4NTRK1 | |
| SCHEMBL1856316 | 0.88 | CSF1R (0.57) | CSF1RKITCYP2C19CYP3A4NTRK1 | |
| SCHEMBL4982409 | 0.88 | CSF1R (0.57) | CSF1RKITCYP2C19CYP3A4NTRK1 | |
| SCHEMBL4980504 | 0.88 | KIT (0.54) | CSF1RKITCYP2C19CYP3A4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296726-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-29 | — | — | US | disclosed |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-8895584-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-28 | — | — | US | disclosed |
| US-8759347-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20130281475-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-24 | — | — | US | disclosed |
| US-8481564-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-09 | — | — | US | disclosed |
| US-8481564-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-09 | — | — | US | disclosed |
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | ILLIG CARL R | 2011-08-11 | — | — | US | disclosed |
| US-7973035-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-07-05 | — | — | US | disclosed |
| US-7973035-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-07-05 | — | — | US | disclosed |
| EP-2021335-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | ILLIG CARL R | 2008-11-06 | — | — | US | disclosed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281475-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885KIT 108/4885CYP2C19 2319/4885 |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, PNCK | CSF1R 249/4885KIT 119/4885CYP2C19 1820/4885 |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885KIT 108/4885CYP2C19 2319/4885 |
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885KIT 108/4885CYP2C19 2319/4885 |
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885KIT 108/4885CYP2C19 2319/4885 |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, CAMK4 | CSF1R 249/4885KIT 214/4885CYP2C19 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.